Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Methods (San Diego, Calif.)|April 26, 2005
Development of humanized antibodies as cancer therapeuticsZhengxing Qu, Gary L Griffiths, William A Wegener, et al.
Rheumatology (Oxford, England)|November 26, 2013
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006Vibeke Strand, Michelle Petri, Kenneth Kalunian, et al.
Leukemia & Lymphoma|September 22, 2015
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemiaMatt E Kalaycio, O George Negrea, Steven L Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumabOla Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, et al.
Haematologica|December 22, 2010
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphomaGeorge O Negrea, Rebecca Elstrom, Steven L Allen, et al.
Haematologica|February 13, 2008
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomographyCaroline Bodet-Milin, Françoise Kraeber-Bodéré, Benoît Dupas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy resultsTorsten Liersch, Johannes Meller, Bettina Kulle, et al.
European Journal of Haematology|August 10, 2013
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principlePatrice Chevallier, Caroline Bodet-Milin, Nelly Robillard, et al.
Pageof 5